1. Revenue from operations ₹1,456 Cr 89% growth Y-o-Y.
2. EBITDA (Before ESOP cost) ₹-393 Cr vs ₹-488 Cr in Q3 FY 2021.
3. EBITDA margin improved to -27% of revenues in Q3 FY 2022 from -63% of revenues in Q3 FY 2021, and -39% of revenues in Q2 FY 2022.
4. ESOP charges of ₹366 Cr recorded in Q3 FY 2022 pertains to grant of 26.6 mn Employee Stock Option (ESOPs) in this quarter.
5. Net Loss for Q3 was ₹778.5 Cr.
6. Net Cash, Cash Equivalent and investable balance of ₹10,215 Cr, as of December 2021.
Business Update
1. Revenue growth was driven by increase in merchant payments processed through MDR (Merchant discount rate )bearing instruments (Paytm Wallet, Paytm bank account, etc), disbursements of loans on platform and recovery of commerce business from covid impact.
2. Average Monthly Transacting Users (MTU), has grown by 37% Y-o-Y to 64.4 mn in Q3 FY 2022.
4. Number of consumers on the platform is now over 350 mn and their merchant base has expanded to 24.9 mn from 20mn a year ago. Company continues to rapidly expand their customer and merchant base.
5. Company earns MDR on the transactions where payment is made through MDR bearing instruments. GMV (Gross merchandise value) from processing payments through MDR bearing instruments grew 77% Y-o-Y. 6. Revenue from payments made by consumers on Paytm App ₹406 Cr 60% YoYgrowth
7. Revenue from Payment Services to Merchants was up 117% YoY and 46% QoQ to ₹586 Cr driven by MDR-bearing payment GMV growth.
8. Revenue from enabling commerce for merchants offerings such as mini apps, advertising and commerce on Paytm App was ₹339 Cr 64% YoY growth.
9. Total Number of Loans Disbursed in Q3 on platform was 4.4mn 401% YoY growth.
10. Value of loans disbursed by their partners using their platform was ₹2,181 Cr 366% YoY growth.
11. Number of Personal Loans disbursed grew 1,187% YoY in Q3 FY22. Personal loans average ticket size ranged from ₹80,000-90,000 with average tenure of 12-14 months.
12. Number of Merchant Loans disbursed grew 38% Y-o-Y in Q3 FY22. Average ticket size continues now at ₹120,000-140,000 with average tenure of 12-14 months. Repeat loans were up, 25% of merchants having taken a loan more than once
13. Company says All of their lending products, Paytm Postpaid (Buy Now Pay Later), Personal Loans and Merchant Loans, have strong market acceptance and are seeing great traction.
14. Company sees great potential in our focussed segments of Wealth, Insurance and Gaming which are growing rapidly in their respective segments.
15. During the quarter, the company launched a new credit card in partnership with HDFC Bank.
16. In January, the company also announced a partnership with Fullerton India to further enhance their credit offerings for their consumers and merchants.
17. RBI has also granted an approval to Paytm Payments Bank to operate as a Scheduled Payments Bank.
18. Paytm Payments Bank launched the Paytm Transit Card, which can be used for travel (metro, railways etc.) to pay toll & parking charges and for online shopping and more.
19. Paytm Payments Bank recorded 926 mn UPI transactions in December 2021.
20. Company also onboarded some large merchants, including a leading ride-sharing company, India’s largest life insurance company, and a leading e-commerce company.
21. Marketing expenses (excluding promotional cashback and incentives) of ₹166 Cr in Q3 FY22, were 11% of revenues.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY
2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore
3. Gross margins in 9M FY22 stood at 41.4%
4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.
3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.